Raloxifene: A new choice for treating and preventing osteoporosis

Article Type
Article
Changed
Wed, 02/13/2019 - 10:02
Display Headline
Raloxifene: A new choice for treating and preventing osteoporosis
Author(s)
Angelo A. Licata, MD, PhD
Angelina V. Ciaccia, PhD
Mayme Wong, PhD
Michael W. Draper, MD, PhD
Article PDF
ccjm67_4-0273.pdf
Author and Disclosure Information

Angelo A. Licata, MD, PhD
Department of Endocrinology, Cleveland Clinic

Angelina V. Ciaccia, PhD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

Mayme Wong, PhD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

Michael W. Draper, MD, PhD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

Address: Angelo A. Licata, MD, PhD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; licataa@ccf.org

Dr. Licata has received grant support from Eli Lilly and Company, which manufactures raloxifene.

Drs. Ciaccia, Wong, and Draper are employees of Eli Lilly and Company.

Issue
Cleveland Clinic Journal of Medicine - 67(4)
Publications
Cleveland Clinic Journal of Medicine
Topics
Drug Therapy
Rheumatology
Preventive Care
Endocrinology
Page Number
273-280
Sections
Reviews
Author(s)
Angelo A. Licata, MD, PhD
Angelina V. Ciaccia, PhD
Mayme Wong, PhD
Michael W. Draper, MD, PhD
Author(s)
Angelo A. Licata, MD, PhD
Angelina V. Ciaccia, PhD
Mayme Wong, PhD
Michael W. Draper, MD, PhD
Author and Disclosure Information

Angelo A. Licata, MD, PhD
Department of Endocrinology, Cleveland Clinic

Angelina V. Ciaccia, PhD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

Mayme Wong, PhD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

Michael W. Draper, MD, PhD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

Address: Angelo A. Licata, MD, PhD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; licataa@ccf.org

Dr. Licata has received grant support from Eli Lilly and Company, which manufactures raloxifene.

Drs. Ciaccia, Wong, and Draper are employees of Eli Lilly and Company.

Author and Disclosure Information

Angelo A. Licata, MD, PhD
Department of Endocrinology, Cleveland Clinic

Angelina V. Ciaccia, PhD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

Mayme Wong, PhD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

Michael W. Draper, MD, PhD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

Address: Angelo A. Licata, MD, PhD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; licataa@ccf.org

Dr. Licata has received grant support from Eli Lilly and Company, which manufactures raloxifene.

Drs. Ciaccia, Wong, and Draper are employees of Eli Lilly and Company.

Article PDF
ccjm67_4-0273.pdf
Article PDF
ccjm67_4-0273.pdf
Related Articles
Of bias, babies, and bathwater
Issue
Cleveland Clinic Journal of Medicine - 67(4)
Issue
Cleveland Clinic Journal of Medicine - 67(4)
Page Number
273-280
Page Number
273-280
Publications
Cleveland Clinic Journal of Medicine
Publications
Cleveland Clinic Journal of Medicine
Topics
Drug Therapy
Rheumatology
Preventive Care
Endocrinology
Article Type
Article
Display Headline
Raloxifene: A new choice for treating and preventing osteoporosis
Display Headline
Raloxifene: A new choice for treating and preventing osteoporosis
Sections
Reviews
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media
Subscribe to Michael W. Draper, MD, PhD